Answers are grounded in this paper and cite their sources.
Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia that occurs due to the pancreas being unable to secrete insulin, insulin resistance, or both. The purpose of this study was to determine the interaction of antidiabetic drugs with other therapies in geriatric patients with type 2 diabetes mellitus. The research method was carried out observationally by collecting medical records retrospectively for the period January - December 2023 at the Haji Hospital, East Java Province. The results of the study showed that the most commonly given therapeutic profile was monotherapy, namely glimepiride (6.0%), combination therapy of two OAD drugs, namely gliquidone with metformin (12.0%), glimepiride with pioglitazone (10.0%), and Pioglitazone with gliclazide (6.0%). The combination therapy of insulin with OAD that is widely used is vildagliptin with ryzodeg (9.0%). In the therapy of giving one type of long-acting insulin, the most frequently used is ryzodeg (85.0%). While in the provision of 2 types of insulin the most are lantus solostar and apidra solostar (6.0%). Interactions with major severity levels are (19.0%) in spironolactone with candesartan, interactions with moderate severity levels are (81.0%) in glimepiride with metformin. While interactions based on pharmacokinetic mechanisms (66.0%) in glimepiride with metformin. Based on pharmacodynamic mechanisms (34.0%) in glimepiride with insulin degludec.
No takes yet. Share an insight, caveat, or question.
Mukti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: